Platelet-derived extracellular vesicles in Huntington’s disease
- 147 Downloads
The production and release of extracellular vesicles (EV) is a property shared by all eukaryotic cells and a phenomenon frequently exacerbated in pathological conditions. The protein cargo of EV, their cell type signature and availability in bodily fluids make them particularly appealing as biomarkers. We recently demonstrated that platelets, among all types of blood cells, contain the highest concentrations of the mutant huntingtin protein (mHtt)—the genetic product of Huntington’s disease (HD), a neurodegenerative disorder which manifests in adulthood with a complex combination of motor, cognitive and psychiatric deficits. Herein, we used a cohort of 59 HD patients at all stages of the disease, including individuals in pre-manifest stages, and 54 healthy age- and sex-matched controls, to evaluate the potential of EV derived from platelets as a biomarker. We found that platelets of pre-manifest and manifest HD patients do not release more EV even if they are activated. Importantly, mHtt was not found within EV derived from platelets, despite them containing high levels of this protein. Correlation analyses also failed to reveal an association between the number of platelet-derived EV and the age of the patients, the number of CAG repeats, the Unified Huntington Disease Rating Scale total motor score, the Total Functional Capacity score or the Burden of Disease score. Our data would, therefore, suggest that EV derived from platelets with HD is not a valuable biomarker in HD.
KeywordsBiomarkers Plasma Immune system Mutant huntingtin protein Huntington’s disease Platelet-derived extracellular vesicles
The study was funded by an operating grant from the Merck Sharpe & Dohme to F. C. who is also a recipient of a Research Chair from the Fonds de Recherche du Québec en santé (FRQS) providing salary support and operating funds. I. S.-A. was supported by a CIHR-Huntington Society of Canada postdoctoral fellowship. R. A. B. and S. L. M. are supported by a National Institute for Health Research (NIHR) award of a Biomedical Research Center to the University of Cambridge and Addenbrooke’s Hospital. E. B. is supported by the Canadian Institutes of Health Research. N. D. MD-MSc. also funded by CIHR and by Canadian Consortium on Neurodegeneration in Aging (CCNA). HLD and JPL hold a Desjardins scholarship from the Fondation du CHU de Québec. HLD hold a bourse d’excellence du Centre Thématique de Recherche en Neurosciences (CTRN) du CHU de Québec. The authors would like to thank all the students and staff who helped with the blood collections in Cambridge, Quebec City and Montreal and importantly, all patients and their families for being so generous with their time for participating in this study.
HLD participated in experiments, data analysis/interpretation and preparation of figures. She wrote the first draft of the manuscript and helped with subsequent revisions. JLP participated in the design of the experiments and various aspects of the study including blood collections, experiments and data analysis. IS-A participated in the design of the experiments and blood collections, took part in some data analysis and interpretation. SLM helped with patient recruitment in Cambridge and participated in the preparation of blood collection. AW performed T-FRET analyses related to Fig. 1i. SC recruited patients in Montreal. RAB recruited patients in Cambridge, participated in data interpretation and revised the manuscript. EB initiated the study and was involved in the experimental design. He also revised the manuscript. FC initiated the study and was involved in the experimental design. She supervised the project and wrote the manuscript.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no competing interests.
- 22.Maglione V, Cannella M, Martino T et al (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington’s disease patients with predominant chorea. Neurosci Lett 393:27–30. https://doi.org/10.1016/j.neulet.2005.09.037 CrossRefPubMedGoogle Scholar
- 26.Silva AC, Almeida S, Laço M et al (2013) Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington’s disease carriers. Mitochondrion 13:801–809. https://doi.org/10.1016/j.mito.2013.05.006 CrossRefPubMedGoogle Scholar
- 33.Bohanna I, Georgiou-Karistianis N, Sritharan A et al (2011) Diffusion tensor imaging in Huntington’s disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav 5:171–180. https://doi.org/10.1007/s11682-011-9121-8 CrossRefPubMedGoogle Scholar
- 43.Olsson MG, Davidsson S, Muhammad ZD et al (2012) Increased levels of hemoglobin and alpha1-microglobulin in Huntington’s disease. Front Biosci (Elite Ed) 4:950–957Google Scholar
- 44.Wood NI, Goodman AOG, van der Burg JMM et al (2008) Increased thirst and drinking in Huntington’s disease and the R6/2 mouse. Brain Res Bull 76:70–79. https://doi.org/10.1016/j.brainresbull.2007.12.007 CrossRefPubMedGoogle Scholar
- 46.Chen X, Guo C, Kong J (2012) Oxidative stress in neurodegenerative diseases. Neural Regener Res 7:376–385. https://doi.org/10.3969/j.issn.1673-5374.2012.05.009 CrossRefGoogle Scholar
- 47.Garrett MC, Soares-da-Silva P (1992) Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington’s disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 58:101–106. https://doi.org/10.1111/j.1471-4159.1992.tb09283.x CrossRefPubMedGoogle Scholar
- 48.Kurlan R, Caine E, Rubin A et al (1988) Cerebrospinal fluid correlates of depression in Huntington’s disease. Arch Neurol 45:881–883. https://doi.org/10.1001/archneur.1988.00520320071018 CrossRefPubMedGoogle Scholar
- 60.Lötvall J, Hill AF, Hochberg F et al (2014) Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 3:26913. https://doi.org/10.3402/jev.v3.26913 CrossRefPubMedGoogle Scholar
- 64.Denis HL, Lamontagne-Proulx J, St-Amour I et al (2018) Platelet abnormalities in Huntington’s disease. J Neurol Neurosurg Psychiatry (in revision) Google Scholar
- 65.Rousseau M, Belleannee C, Duchez A-C et al (2015) Detection and quantification of microparticles from different cellular lineages using flow cytometry. Evaluation of the impact of secreted phospholipase A2 on microparticle assessment. PLoS One 10:e0116812. https://doi.org/10.1371/journal.pone.0116812 CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Lamontagne-Proulx J, St-Amour I, Labib R et al (2018) Erythrocyte-derived extracellular vesicles: a novel, robust and specific biomarker that maps to Parkinson’s disease stages. Neuro Dis (Under review) Google Scholar